BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17671710)

  • 1. Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler.
    Sasaki H; Okuda K; Kawano O; Endo K; Yukiue H; Yokoyama T; Yano M; Fujii Y
    Oncol Rep; 2007 Sep; 18(3):623-8. PubMed ID: 17671710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
    Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
    J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer.
    Sasaki H; Hikosaka Y; Kawano O; Moriyama S; Yano M; Fujii Y
    J Thorac Oncol; 2011 Jan; 6(1):15-20. PubMed ID: 21150464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
    Sasaki H; Endo K; Konishi A; Takada M; Kawahara M; Iuchi K; Matsumura A; Okumura M; Tanaka H; Kawaguchi T; Shimizu T; Takeuchi H; Yano M; Fukai I; Fujii Y
    Clin Cancer Res; 2005 Apr; 11(8):2924-9. PubMed ID: 15837743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.
    Shibata T; Hanada S; Kokubu A; Matsuno Y; Asamura H; Ohta T; Sakamoto M; Hirohashi S
    Cancer Sci; 2007 Jul; 98(7):985-91. PubMed ID: 17459062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma.
    Vagaja NN; Parry J; McCallum D; Thomas MA; Bentel JM
    J Clin Pathol; 2015 Aug; 68(8):657-60. PubMed ID: 25926041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.
    Raparia K; Villa C; Raj R; Cagle PT
    Arch Pathol Lab Med; 2015 Feb; 139(2):189-93. PubMed ID: 24694341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
    Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
    J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival in ampullary cancer: potential role of different KRAS mutations.
    Valsangkar NP; Ingkakul T; Correa-Gallego C; Mino-Kenudson M; Masia R; Lillemoe KD; Fernández-del Castillo C; Warshaw AL; Liss AS; Thayer SP
    Surgery; 2015 Feb; 157(2):260-8. PubMed ID: 25616942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
    Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of lung cancers harboring NRAS mutations.
    Ohashi K; Sequist LV; Arcila ME; Lovly CM; Chen X; Rudin CM; Moran T; Camidge DR; Vnencak-Jones CL; Berry L; Pan Y; Sasaki H; Engelman JA; Garon EB; Dubinett SM; Franklin WA; Riely GJ; Sos ML; Kris MG; Dias-Santagata D; Ladanyi M; Bunn PA; Pao W
    Clin Cancer Res; 2013 May; 19(9):2584-91. PubMed ID: 23515407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of specific KRAS mutations in lung adenocarcinomas.
    Siegfried JM; Gillespie AT; Mera R; Casey TJ; Keohavong P; Testa JR; Hunt JD
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):841-7. PubMed ID: 9332768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR and KRAS mutations in patients with adenocarcinoma of the lung.
    Jang TW; Oak CH; Chang HK; Suo SJ; Jung MH
    Korean J Intern Med; 2009 Mar; 24(1):48-54. PubMed ID: 19270482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
    Paulsson K; Horvat A; Strömbeck B; Nilsson F; Heldrup J; Behrendtz M; Forestier E; Andersson A; Fioretos T; Johansson B
    Genes Chromosomes Cancer; 2008 Jan; 47(1):26-33. PubMed ID: 17910045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer.
    Uchiyama M; Usami N; Kondo M; Mori S; Ito M; Ito G; Yoshioka H; Imaizumi M; Ueda Y; Takahashi M; Minna JD; Shimokata K; Sekido Y
    Int J Cancer; 2003 Dec; 107(6):962-9. PubMed ID: 14601056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.
    Yokoyama T; Kondo M; Goto Y; Fukui T; Yoshioka H; Yokoi K; Osada H; Imaizumi K; Hasegawa Y; Shimokata K; Sekido Y
    Cancer Sci; 2006 Aug; 97(8):753-9. PubMed ID: 16863509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.
    Villaruz LC; Socinski MA; Cunningham DE; Chiosea SI; Burns TF; Siegfried JM; Dacic S
    Cancer; 2013 Jun; 119(12):2268-74. PubMed ID: 23526491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.
    Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J
    Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.